Injury type-dependent differentiation of NG2 glia into heterogeneous astrocytes

Amber R. Hackett, Stephanie L. Yahn, Kirill Lyapichev, Angela Dajnoki, Do Hun Lee, Mario Rodriguez, Natasha Cammer, Ji Pak, Saloni T. Mehta, Olaf Bodamer, Vance Lemmon, Jae Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The glial scar is comprised of a heterogeneous population of reactive astrocytes. NG2 glial cells (also known as oligodendrocyte progenitor cells or polydendrocytes) may contribute to this heterogeneity by differentiating into astrocytes in the injured CNS, but there have been conflicting reports about whether astrocytes comprise a significant portion of the NG2 cell lineage. By using genetic fate mapping after spinal cord injury (SCI) and experimental autoimmune encephalomyelitis (EAE) in mice, the goal of this study was to confirm and extend upon previous findings, which have shown that NG2 cell plasticity varies across CNS injuries. We generated mice that express tdTomato in NG2 lineage cells and express GFP under the Aldh1l1 or Glt1 promoter so that NG2 glia-derived astrocytes can be detected by their expression of GFAP and/or GFP. We found that astrocytes comprise approximately 25% of the total NG2 cell lineage in the glial scar by 4 weeks after mid-thoracic contusive SCI, but only 9% by the peak of functional deficit after EAE. Interestingly, a subpopulation of astrocytes expressed only GFP without co-expression of GFAP, uncovering their heterogeneity and the possibility of an underestimation of NG2 glia-derived astrocytes in previous studies. Additionally, we used high performance liquid chromatography to measure the level of tamoxifen and its metabolites in the spinal cord and show that genetic labeling of NG2 glia-derived astrocytes is not an artifact of residual tamoxifen. Overall, our data demonstrate that a heterogeneous population of astrocytes are derived from NG2 glia in an injury type-dependent manner.

Original languageEnglish (US)
Pages (from-to)72-79
Number of pages8
JournalExperimental Neurology
Volume308
DOIs
StatePublished - Oct 1 2018

Fingerprint

Neuroglia
Astrocytes
Wounds and Injuries
Autoimmune Experimental Encephalomyelitis
Cell Lineage
Tamoxifen
Spinal Cord Injuries
Cicatrix
Oligodendroglia
Artifacts
Population
Spinal Cord
Thorax
Stem Cells
High Pressure Liquid Chromatography

Keywords

  • Astrocyte heterogeneity
  • Astrocytes
  • Experimental autoimmune encephalomyelitis
  • Glial scar
  • Oligodendrocyte progenitor cells
  • Spinal cord injury
  • Tamoxifen

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Injury type-dependent differentiation of NG2 glia into heterogeneous astrocytes. / Hackett, Amber R.; Yahn, Stephanie L.; Lyapichev, Kirill; Dajnoki, Angela; Lee, Do Hun; Rodriguez, Mario; Cammer, Natasha; Pak, Ji; Mehta, Saloni T.; Bodamer, Olaf; Lemmon, Vance; Lee, Jae.

In: Experimental Neurology, Vol. 308, 01.10.2018, p. 72-79.

Research output: Contribution to journalArticle

Hackett, AR, Yahn, SL, Lyapichev, K, Dajnoki, A, Lee, DH, Rodriguez, M, Cammer, N, Pak, J, Mehta, ST, Bodamer, O, Lemmon, V & Lee, J 2018, 'Injury type-dependent differentiation of NG2 glia into heterogeneous astrocytes', Experimental Neurology, vol. 308, pp. 72-79. https://doi.org/10.1016/j.expneurol.2018.07.001
Hackett, Amber R. ; Yahn, Stephanie L. ; Lyapichev, Kirill ; Dajnoki, Angela ; Lee, Do Hun ; Rodriguez, Mario ; Cammer, Natasha ; Pak, Ji ; Mehta, Saloni T. ; Bodamer, Olaf ; Lemmon, Vance ; Lee, Jae. / Injury type-dependent differentiation of NG2 glia into heterogeneous astrocytes. In: Experimental Neurology. 2018 ; Vol. 308. pp. 72-79.
@article{4f22ec3e0413421bae2b7adf799e197c,
title = "Injury type-dependent differentiation of NG2 glia into heterogeneous astrocytes",
abstract = "The glial scar is comprised of a heterogeneous population of reactive astrocytes. NG2 glial cells (also known as oligodendrocyte progenitor cells or polydendrocytes) may contribute to this heterogeneity by differentiating into astrocytes in the injured CNS, but there have been conflicting reports about whether astrocytes comprise a significant portion of the NG2 cell lineage. By using genetic fate mapping after spinal cord injury (SCI) and experimental autoimmune encephalomyelitis (EAE) in mice, the goal of this study was to confirm and extend upon previous findings, which have shown that NG2 cell plasticity varies across CNS injuries. We generated mice that express tdTomato in NG2 lineage cells and express GFP under the Aldh1l1 or Glt1 promoter so that NG2 glia-derived astrocytes can be detected by their expression of GFAP and/or GFP. We found that astrocytes comprise approximately 25{\%} of the total NG2 cell lineage in the glial scar by 4 weeks after mid-thoracic contusive SCI, but only 9{\%} by the peak of functional deficit after EAE. Interestingly, a subpopulation of astrocytes expressed only GFP without co-expression of GFAP, uncovering their heterogeneity and the possibility of an underestimation of NG2 glia-derived astrocytes in previous studies. Additionally, we used high performance liquid chromatography to measure the level of tamoxifen and its metabolites in the spinal cord and show that genetic labeling of NG2 glia-derived astrocytes is not an artifact of residual tamoxifen. Overall, our data demonstrate that a heterogeneous population of astrocytes are derived from NG2 glia in an injury type-dependent manner.",
keywords = "Astrocyte heterogeneity, Astrocytes, Experimental autoimmune encephalomyelitis, Glial scar, Oligodendrocyte progenitor cells, Spinal cord injury, Tamoxifen",
author = "Hackett, {Amber R.} and Yahn, {Stephanie L.} and Kirill Lyapichev and Angela Dajnoki and Lee, {Do Hun} and Mario Rodriguez and Natasha Cammer and Ji Pak and Mehta, {Saloni T.} and Olaf Bodamer and Vance Lemmon and Jae Lee",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.expneurol.2018.07.001",
language = "English (US)",
volume = "308",
pages = "72--79",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Injury type-dependent differentiation of NG2 glia into heterogeneous astrocytes

AU - Hackett, Amber R.

AU - Yahn, Stephanie L.

AU - Lyapichev, Kirill

AU - Dajnoki, Angela

AU - Lee, Do Hun

AU - Rodriguez, Mario

AU - Cammer, Natasha

AU - Pak, Ji

AU - Mehta, Saloni T.

AU - Bodamer, Olaf

AU - Lemmon, Vance

AU - Lee, Jae

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The glial scar is comprised of a heterogeneous population of reactive astrocytes. NG2 glial cells (also known as oligodendrocyte progenitor cells or polydendrocytes) may contribute to this heterogeneity by differentiating into astrocytes in the injured CNS, but there have been conflicting reports about whether astrocytes comprise a significant portion of the NG2 cell lineage. By using genetic fate mapping after spinal cord injury (SCI) and experimental autoimmune encephalomyelitis (EAE) in mice, the goal of this study was to confirm and extend upon previous findings, which have shown that NG2 cell plasticity varies across CNS injuries. We generated mice that express tdTomato in NG2 lineage cells and express GFP under the Aldh1l1 or Glt1 promoter so that NG2 glia-derived astrocytes can be detected by their expression of GFAP and/or GFP. We found that astrocytes comprise approximately 25% of the total NG2 cell lineage in the glial scar by 4 weeks after mid-thoracic contusive SCI, but only 9% by the peak of functional deficit after EAE. Interestingly, a subpopulation of astrocytes expressed only GFP without co-expression of GFAP, uncovering their heterogeneity and the possibility of an underestimation of NG2 glia-derived astrocytes in previous studies. Additionally, we used high performance liquid chromatography to measure the level of tamoxifen and its metabolites in the spinal cord and show that genetic labeling of NG2 glia-derived astrocytes is not an artifact of residual tamoxifen. Overall, our data demonstrate that a heterogeneous population of astrocytes are derived from NG2 glia in an injury type-dependent manner.

AB - The glial scar is comprised of a heterogeneous population of reactive astrocytes. NG2 glial cells (also known as oligodendrocyte progenitor cells or polydendrocytes) may contribute to this heterogeneity by differentiating into astrocytes in the injured CNS, but there have been conflicting reports about whether astrocytes comprise a significant portion of the NG2 cell lineage. By using genetic fate mapping after spinal cord injury (SCI) and experimental autoimmune encephalomyelitis (EAE) in mice, the goal of this study was to confirm and extend upon previous findings, which have shown that NG2 cell plasticity varies across CNS injuries. We generated mice that express tdTomato in NG2 lineage cells and express GFP under the Aldh1l1 or Glt1 promoter so that NG2 glia-derived astrocytes can be detected by their expression of GFAP and/or GFP. We found that astrocytes comprise approximately 25% of the total NG2 cell lineage in the glial scar by 4 weeks after mid-thoracic contusive SCI, but only 9% by the peak of functional deficit after EAE. Interestingly, a subpopulation of astrocytes expressed only GFP without co-expression of GFAP, uncovering their heterogeneity and the possibility of an underestimation of NG2 glia-derived astrocytes in previous studies. Additionally, we used high performance liquid chromatography to measure the level of tamoxifen and its metabolites in the spinal cord and show that genetic labeling of NG2 glia-derived astrocytes is not an artifact of residual tamoxifen. Overall, our data demonstrate that a heterogeneous population of astrocytes are derived from NG2 glia in an injury type-dependent manner.

KW - Astrocyte heterogeneity

KW - Astrocytes

KW - Experimental autoimmune encephalomyelitis

KW - Glial scar

KW - Oligodendrocyte progenitor cells

KW - Spinal cord injury

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85049592273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049592273&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2018.07.001

DO - 10.1016/j.expneurol.2018.07.001

M3 - Article

C2 - 30008424

AN - SCOPUS:85049592273

VL - 308

SP - 72

EP - 79

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -